Marrone partners with Éléphant Vert

Marrone Bio Innovations and Éléphant Vert announce their partnership to distribute two novel biopesticides for sustainable farming in North Africa: Reysana Biofungicide and Majestene Bionematicide.

Together, these two players of the biological crop protection market have the products and knowledge to bring sustainable solutions for improving both yield and quality to farmers in North Africa.

Éléphant Vert will develop and market two of MBI’s products in Morocco, Tunisia and Algeria:
  • The biofungicide Reysana is currently labeled for use by growers of tomatoes, peppers, grapes and cucurbits. Reysana contains the same ingredients as MBI’s Regalia Maxx Biofungicide, which is already marketed and sold in more than 10 countries worldwide.
  • The bionematicide Majestene, which protects crops from yield-robbing nematodes. The product is in the registration process.
Vincent Thieyre, Products & Solutions Development Director of Éléphant Vert, said: “Integrating biopesticides into crop protection programs benefits all production, and is increasingly important for exporters of vegetables in the region. Growers of key crops in Morocco are eagerly awaiting Reysana’s official launch event in Agadir on September 21st 2017, followed by a similar event in Tunisia. These events are significant milestones that solidify the cooperation between our two companies.”

Dr. Pamela Marrone, CEO and Founder of MBI said: “We are delighted by this partnership that is part of our international development strategy; this agreement enables MBI to expand to new markets in North Africa while meeting farmers’ needs with innovation-driven biological products.”

Sébastien Couasnet, CEO of Éléphant Vert, added, “This agreement opens up new promising development opportunities to provide North-African farmers with a wider range of natural, efficient and innovative solutions.”

For more information:

Publication date:

Receive the daily newsletter in your email for free | Click here

Other news in this sector:

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.

Click here for a guide on disabling your adblocker.